...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Lack of mania prophylaxis associated with lamotrigine monotherapy in manic-predominant bipolar I disorder.
【24h】

Lack of mania prophylaxis associated with lamotrigine monotherapy in manic-predominant bipolar I disorder.

机译：在以躁狂为主的双相性I障碍中缺乏与拉莫三嗪单药治疗相关的躁狂预防。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Sir: Unlike all other mood-stabilizing drugs, lamotrigine does not have an indication for acute mania. The maintenance indication for lamotrigine is based on two 18-month studies evaluating time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in bipolar I patients treated for acute mood episodes with standard therapy. Only when these 2 studies were analyzed together (a priori determined to increase statistical power) was the superiority of lamotrigine over placebo in delaying the time to intervention for a manic episode evident. As the following case reports highlight, lamotrigine may have limitations as monotherapy for mania prophylaxis in DSM-IV manic-predominant bipolar I disorder.
机译：主席先生：与所有其他稳定情绪的药物不同，拉莫三嗪没有急性躁狂症的征兆。拉莫三嗪的维持适应症基于两项18个月的研究，评估了接受标准疗法治疗的急性情感发作的双相I患者的情感发作（抑郁，躁狂，轻躁狂，混合发作）发生的时间。只有同时分析了这两项研究（先验确定可提高统计功效），拉莫三嗪在安慰剂发作的延迟时间上才优于安慰剂。正如以下病例报道所强调的那样，拉莫三嗪作为单一疗法在预防DSM-IV躁狂为主的双相性I型躁狂中可能存在局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号